Published in Clin Ther on June 01, 2005
Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol (2010) 3.80
Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol Ther (2007) 3.03
RNA-binding protein quaking, a critical regulator of colon epithelial differentiation and a suppressor of colon cancer. Gastroenterology (2009) 1.29
Sequencing of type I insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivo. Clin Cancer Res (2009) 1.10
Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines. J Nucl Med (2008) 1.07
Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model. Clin Cancer Res (2011) 1.03
Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: results of a multicenter study. Support Care Cancer (2008) 0.98
Stem cell factor/c-kit receptor signaling enhances the proliferation and invasion of colorectal cancer cells through the PI3K/Akt pathway. Dig Dis Sci (2007) 0.98
Inductive tissue engineering with protein and DNA-releasing scaffolds. Mol Biosyst (2005) 0.94
Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response. Mol Cancer (2009) 0.90
Anaphylactic reactions to oligosaccharides in red meat: a syndrome in evolution. Clin Mol Allergy (2012) 0.89
Characterization of aneuploid populations with trisomy 7 and 20 derived from diploid human colonic epithelial cells. Neoplasia (2011) 0.87
Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers. Br J Cancer (2015) 0.82
Combined effects of 5-fluorouracil, folinic acid and oxaliplatin on the expression of carcinoembryonic antigen in human colon cancer cells: pharmacological basis to develop an active antitumor immunochemotherapy. J Exp Clin Cancer Res (2008) 0.82
Graphene nanoribbons elicit cell specific uptake and delivery via activation of epidermal growth factor receptor enhanced by human papillomavirus E5 protein. Acta Biomater (2014) 0.82
Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10. Br J Cancer (2012) 0.80
Co-expression of HER family members in patients with Dukes' C and D colon cancer and their impacts on patient prognosis and survival. PLoS One (2014) 0.79
EGF receptor-targeted nanocarriers for enhanced cancer treatment. Nanomedicine (Lond) (2012) 0.79
Incidence and risk of treatment-related mortality with anti-epidermal growth factor receptor monoclonal antibody in cancer patients: a meta-analysis of 21 randomized controlled trials. PLoS One (2013) 0.78
Investigating the antiproliferative activity of high affinity DNA aptamer on cancer cells. PLoS One (2013) 0.78
The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer. Oncotarget (2016) 0.75
Screening and identification of the tumor-associated antigen CK10, a novel potential liver cancer marker. FEBS Open Bio (2017) 0.75
Protein Kinase G facilitates EGFR-mediated cell death in MDA-MB-468 cells. Exp Cell Res (2016) 0.75
Antitumor Activity of HM781-36B, alone or in Combination with Chemotherapeutic Agents, in Colorectal Cancer Cells. Cancer Res Treat (2015) 0.75
EGFR-mediated apoptosis via STAT3. Exp Cell Res (2017) 0.75